Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Abstract Several studies have evaluated immune checkpoint inhibitors (ICIs) for metastatic uveal melanoma; however, the efficacy of ICIs in the previous studies varied greatly. In this systematic review, we searched for prospective or retrospective studies on single or dual-ICIs for metastatic uveal...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-55675-5 |
| _version_ | 1797219781286297600 |
|---|---|
| author | Kayoko Yamada Masaki Takeuchi Takeshi Fukumoto Minako Suzuki Ai Kato Yuki Mizuki Norihiro Yamada Takeshi Kaneko Nobuhisa Mizuki Nobuyuki Horita |
| author_facet | Kayoko Yamada Masaki Takeuchi Takeshi Fukumoto Minako Suzuki Ai Kato Yuki Mizuki Norihiro Yamada Takeshi Kaneko Nobuhisa Mizuki Nobuyuki Horita |
| author_sort | Kayoko Yamada |
| collection | DOAJ |
| description | Abstract Several studies have evaluated immune checkpoint inhibitors (ICIs) for metastatic uveal melanoma; however, the efficacy of ICIs in the previous studies varied greatly. In this systematic review, we searched for prospective or retrospective studies on single or dual-ICIs for metastatic uveal melanoma treatment. A random-effect model meta-analysis with generic inverse-variance was conducted, and 36 articles representing 41 cohorts of 1414 patients with metastatic uveal melanoma were included. The pooled outcomes were as follows: objective response rate (ORR) was 5.6% (95% confidence interval [95%CI] 3.7–7.5%; I2, 36%), disease control rate (DCR) was 32.5% (95% CI 27.2–37.7%; I2, 73%), median progression-free survival was 2.8 months (95% CI 2.7–2.9 months; I2, 26%), and median overall survival (OS) was 11.2 months (95% CI 9.6–13.2 months; I2, 74%). Compared to single-agent ICI, dual ICI led to better ORR (single-agent: 3.4% [95% CI 1.8–5.1]; dual-agent: 12.4% [95% CI 8.0–16.9]; P < 0.001), DCR (single-agent: 29.3%, [95% CI 23.4–35.2]; dual-agent: 44.3% [95% CI 31.7–56.8]; P = 0.03), and OS (single-agent: 9.8 months [95% CI 8.0–12.2]; dual-agent: 16.3 months [95% CI 13.5–19.7]; P < 0.001). Our analysis provided treatment outcomes as described above. Dual-ICIs appear better than single-agent ICIs for the treatment of metastatic uveal melanoma. |
| first_indexed | 2024-04-24T12:39:06Z |
| format | Article |
| id | doaj.art-237cd7ff7fb44bf896a7ef9f53d992f3 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-24T12:39:06Z |
| publishDate | 2024-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-237cd7ff7fb44bf896a7ef9f53d992f32024-04-07T11:19:09ZengNature PortfolioScientific Reports2045-23222024-04-0114111110.1038/s41598-024-55675-5Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysisKayoko Yamada0Masaki Takeuchi1Takeshi Fukumoto2Minako Suzuki3Ai Kato4Yuki Mizuki5Norihiro Yamada6Takeshi Kaneko7Nobuhisa Mizuki8Nobuyuki Horita9Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of MedicineDepartment of Ophthalmology and Visual Science, Yokohama City University Graduate School of MedicineDivision of Dermatology, Department of Internal Related, Kobe University Graduate School of MedicineDepartment of Ophthalmology and Visual Science, Yokohama City University Graduate School of MedicineDepartment of Ophthalmology and Visual Science, Yokohama City University Graduate School of MedicineDepartment of Ophthalmology and Visual Science, Yokohama City University Graduate School of MedicineDepartment of Ophthalmology and Visual Science, Yokohama City University Graduate School of MedicineDepartment of Pulmonology, Yokohama City University Graduate School of MedicineDepartment of Ophthalmology and Visual Science, Yokohama City University Graduate School of MedicineChemotherapy Center, Yokohama City University HospitalAbstract Several studies have evaluated immune checkpoint inhibitors (ICIs) for metastatic uveal melanoma; however, the efficacy of ICIs in the previous studies varied greatly. In this systematic review, we searched for prospective or retrospective studies on single or dual-ICIs for metastatic uveal melanoma treatment. A random-effect model meta-analysis with generic inverse-variance was conducted, and 36 articles representing 41 cohorts of 1414 patients with metastatic uveal melanoma were included. The pooled outcomes were as follows: objective response rate (ORR) was 5.6% (95% confidence interval [95%CI] 3.7–7.5%; I2, 36%), disease control rate (DCR) was 32.5% (95% CI 27.2–37.7%; I2, 73%), median progression-free survival was 2.8 months (95% CI 2.7–2.9 months; I2, 26%), and median overall survival (OS) was 11.2 months (95% CI 9.6–13.2 months; I2, 74%). Compared to single-agent ICI, dual ICI led to better ORR (single-agent: 3.4% [95% CI 1.8–5.1]; dual-agent: 12.4% [95% CI 8.0–16.9]; P < 0.001), DCR (single-agent: 29.3%, [95% CI 23.4–35.2]; dual-agent: 44.3% [95% CI 31.7–56.8]; P = 0.03), and OS (single-agent: 9.8 months [95% CI 8.0–12.2]; dual-agent: 16.3 months [95% CI 13.5–19.7]; P < 0.001). Our analysis provided treatment outcomes as described above. Dual-ICIs appear better than single-agent ICIs for the treatment of metastatic uveal melanoma.https://doi.org/10.1038/s41598-024-55675-5 |
| spellingShingle | Kayoko Yamada Masaki Takeuchi Takeshi Fukumoto Minako Suzuki Ai Kato Yuki Mizuki Norihiro Yamada Takeshi Kaneko Nobuhisa Mizuki Nobuyuki Horita Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis Scientific Reports |
| title | Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis |
| title_full | Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis |
| title_fullStr | Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis |
| title_full_unstemmed | Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis |
| title_short | Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis |
| title_sort | immune checkpoint inhibitors for metastatic uveal melanoma a meta analysis |
| url | https://doi.org/10.1038/s41598-024-55675-5 |
| work_keys_str_mv | AT kayokoyamada immunecheckpointinhibitorsformetastaticuvealmelanomaametaanalysis AT masakitakeuchi immunecheckpointinhibitorsformetastaticuvealmelanomaametaanalysis AT takeshifukumoto immunecheckpointinhibitorsformetastaticuvealmelanomaametaanalysis AT minakosuzuki immunecheckpointinhibitorsformetastaticuvealmelanomaametaanalysis AT aikato immunecheckpointinhibitorsformetastaticuvealmelanomaametaanalysis AT yukimizuki immunecheckpointinhibitorsformetastaticuvealmelanomaametaanalysis AT norihiroyamada immunecheckpointinhibitorsformetastaticuvealmelanomaametaanalysis AT takeshikaneko immunecheckpointinhibitorsformetastaticuvealmelanomaametaanalysis AT nobuhisamizuki immunecheckpointinhibitorsformetastaticuvealmelanomaametaanalysis AT nobuyukihorita immunecheckpointinhibitorsformetastaticuvealmelanomaametaanalysis |